Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claudia Vidal

Dermatopathology Bloomington, IN Medical Doctor

NPI 1790944742 CMS profile 585070

1200 S Rogers St, Bloomington, IN 47403

Open in the dashboard

General payments

$3,820

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claudia Vidal of Bloomington, IN is reported in the CMS Open Payments database as having received $3,820 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatopathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $984 45
2024 General $991 48
2023 General $794 35
2022 General $631 36
2021 General $204 11
2020 General $91 6
2019 General $124 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claudia Vidal
  • Dermatopathology median
  • Middle half of Dermatopathology
  • National median

In program year 2025, general payments to Claudia Vidal were reported at $984. Among 101 Dermatopathology profiles paid that year, the median was $119 and the middle half received between $30 and $257.

Show as a table
Year Claudia Vidal Dermatopathology median Middle half National median
2019 $124 $104 $28–$168 $163
2020 $91 $65 $26–$232 $114
2021 $204 $91 $29–$138 $132
2022 $631 $119 $24–$265 $149
2023 $794 $107 $44–$267 $160
2024 $991 $123 $33–$272 $164
2025 $984 $119 $30–$257 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $565 28 payments
  2. Novartis Pharmaceuticals Corporation $460 22 payments
  3. Lilly USA, LLC $382 16 payments
  4. Regeneron Healthcare Solutions, Inc. $346 17 payments
  5. LEO Pharma Inc. $336 22 payments
  6. Amgen Inc. $326 17 payments
  7. Incyte Corporation $310 14 payments
  8. UCB, Inc. $245 11 payments
  9. Genzyme Corporation $181 10 payments
  10. Janssen Biotech, Inc. $147 8 payments
  11. Other $522 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,820 189 payments
Products named General payments · program years 2019–2025
  1. ILUMYA $516 25 payments
  2. COSENTYX $395 19 payments
  3. Otezla $311 16 payments
  4. OPZELURA $310 14 payments
  5. ADBRY $294 19 payments
  6. DUPIXENT Inflammation And Immunology $270 13 payments
  7. OLUMIANT $267 9 payments
  8. DUPIXENT Immunology $260 14 payments
  9. TALTZ $259 15 payments
  10. Bimzelx $218 9 payments
  11. Other $1,119 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$353,383

Medicare's payments for the services billed

Medicare patients

2,909

Average age 76

Services billed

7,385

1,429 women, 1,480 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 27%
Ischemic heart disease 24%
Chronic kidney disease 22%
Atrial fibrillation 18%
Depression 18%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
$190 — —
DUPIXENT
$161 — —
OPZELURA
$158 — —
Otezla
$130 — —
ILUMYA
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatopathology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record